Here we report that Histone deacetylase inhibitors (HDAC-i) comprise a new class of immunosuppressive agents.
Introduction
HDAC-i are potent inducers of apoptosis and growth inhibition in a variety of transformed cells in vitro and in vivo, including malignancies originating from lymphoid cells [1] [2] [3] . On the other hand HDAC-i are relatively nontoxic to normal cells, when measured by viability 2 , making pharmacological reagents with histone deacetylase inhibitory activity good candidates for novel anti-tumor therapy.
Several different agents have been identified as having HDAC-i activity, including
Trichostatin A, Trapoxin, Oxamflatin, apicidin, phenylbutyrate, suberoylanilide hydroxamic acid (SAHA), pyroxamide and FR901228, where at least the last four are currently in clinical trials for evaluation of their anti-cancer efficacy 4 .
Histones are core structural components of nucleosomes and play a key role in regulating DNA accessibility to transcriptional regulation. DNA is normally tightly wrapped around A number of proteins other than histones are affected by acetylation, these include transcription factors such as p53 and GATA-1 5;6 . Moreover, transcription factors such as p300, Rb, GCN5, P/CAF and Blimp-1 possess/recruit HDAC or HAT activity [7] [8] [9] . Given
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From the broad spectrum of activities mediated by HDAC-i it is interesting that only a small number of genes are affected 10 . It is currently believed that the initial regulation of gene expression is predominantly regulated by modulation of the promotor acelylation grade through recruitment of transcription factors possessing HDAC/HAT activity.
Several groups have studied HDAC-i mediated apoptosis and growth inhibition of tumor cells. HDAC-i induces transcriptional activation and protein expression of the cyclin kinase inhibitor p21 cip/waf 11;12 and p21 cip/waf expression has been shown to be essential for butyrate induced growth inhibition of human colon cancer cells 12 . In agreement with this, Sandor et al. showed that p21 cip/waf negative NIH3T3 cells lack the ability to be arrested in G1 by FR901228 13 .
A number of groups have shown that HDAC-i inhibits the constitutive expression of the c-Myc proto-oncogene in various tumor and established cell lines 3;15 . C-myc is an immediate early gene that is involved in both proliferation and apoptosis of normal cells 16;17 . Inhibition of c-Myc was previously shown not to be involved in HDAC-i induced apoptosis of human leukemic lymphoblasts, as transgeneic expression of c-Myc could not inhibit the induction of apoptosis 18 .
Stra13 is a transcriptional repressor induced by Trichostatin A and ectopic expression of
Stra13 inhibits growth of NIH 3T3 cells 19 . It is therefore possible that Stra13 expression is causally involved in HDAC-i mediated growth inhibition, however experiments with cells containing nonfunctional or deleted Stra13 are required to confirm this hypothesis.
Interestingly, Stra13 expression strongly suppresses c-Myc promotor activity in vitro 19 , making Stra13 expression a possible link to the molecular mechanism behind HDAC-i inhibition of c-Myc expression.
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From FR901228 has been shown to inhibit the constitutive Fas ligand expression in A1.1 T cells, which correlated with inhibition of c-Myc expression 15 . C-Myc was later showed to be involved in FasL expression through a previously unrecognized c-Myc DNA binding domain in the proximal FasL promoter 20 . It is therefore tempting to speculate that FR901228 inhibits FasL expression through inhibition of c-Myc expression, although an unrecognized effect of FR901228 cannot be ruled out with the current knowledge.
Trichostatin A has been shown to partially inhibit IL-2 signaling in IL-2 dependent hematopoietic cell lines. IL-2 induction of c-myc, bag-1 and LC-PTP was abolished by Trichostatin A; in contrast, IL-2 mediated phosphorylation of SHP-2, Jak1 and Stat5 was not affected, demonstrating specificity of the inhibition 21 . Trichostatin A has furthermore been shown to reverse the abnormal expression of CD154, IL-10 and IFN-γ in SLE T cells 22 .
Identification and characterization of novel T cell inhibitory compounds is important for creating new strategies to prevent autoimmune diseases and graft rejection. Although
Cyclosporine and FK-506 effectively suppress activation of naive T cells, they are poor inhibitors of ongoing effector immune responses, reflected in their poor therapeutical effect towards autoimmune diseases.
In this study we describe the immunosuppressive activity of HDAC-i, which, in contrast to previously known immunosuppressors, is able to effectively inhibit CD154 expression on effector T cells, suggesting that this may pave the road for development of effective inhibitors of ongoing immune responses.
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Methods

Cells, antibodies, chemicals
All cells isolated from human blood were grown in media supplemented with 20 U/ml IL-2 (Boehringer Mannheim), 5% human serum or 5% FBS, 2 mM Glutamine and 20 mM Hepes. Jurkat cells were grown in RPMI 1640 supplemented with 10% FBS, 2 mM glutamine, 2 mM Penicillin and Streptomycin.
Buffy coats from healthy human volunteer donors were obtained from the State Hospital, Copenhagen, Denmark. Peripheral blood mononuclear cells (PBMC) were obtained using Lymphocyte Separation Media (ICN) according to the manufactures' description.
Peripheral blood lymphocytes (PBL) were obtained from the PBMC fraction by incubation in culture flask with uncoated dynabeads (Dynal), 2 beads/cell, 2h at 37°C.
Monocytes and macrophages stick to the culture flask or phagocytose the paramagnetic beads that were depleted by magnetic cell separation (Dynal). CD4 cells were purified from the PBL fraction by incubation with 10 ug/ml of monoclonal antibodies against CD8 (G10-1, ATCC), CD20 (IF5, ATCC), CD14 (F13, ATCC) and CD16 (Coulter), 20 min at 4°C. After washing, cells were depleted twice with swine anti-mouse Ig-coupled dynabeads (6 beads/cell, 20 min at 4°C) followed by magnetic cell separation. The purity of CD4 cells was routinely 91-95% measured by Flow cytometry.
Dendritic cells were generated from PBMC adhering to the culture flask after 2h culture at 37°C (without dynabeads). After extensive washing, adhering cells were cultured for 7 days in media containing 500 U/ml GM-CSF (Boehringer mannheim) and 12.5 U/ml IL-4 (Boehringer Mannheim). The resulting cell population was weakly adherent and 
Measurement of proliferation
Proliferation assay was performed in quadruplicates in 96 well flat-bottom plates. Cells were stimulated at 10 6 cell/ml in a final volume of 200 ul. Proliferation was measured by MTT assay (10 ug/ml MTT, 4h at 37°C) or by Flow cytometric analysis of CFDA-SE stained cells (Cells were stained 1 uM CFDA-SE for 10 min at 25°C and washed extensively prior to stimulation).
Flow cytometry
Cells were labeled with FITC or PE coupled antibodies: anti-human CD4 Ab (Immunotech), anti-human CD8 Ab (Pharmingen), anti-human CD25 Ab (Becton 
Measurement of intracellular Calcium concentration
Measurement of intracellular calcium concentration after anti-CD3 stimulation was done on Fura-2 loaded PBLs as described in 23 .
ELISA
Cytokine production was analyzed by sandwich ELISA using the manufacturer's protocol (Pharmingen/BectonDickinson).
Construction of CD154 promotor-EGFP construct
Approximately 2kb upstream from the CD154 transcription start was PCR cloned from a Jurkat E6-1 DNA preparation using primer-set: 5'ggggtaccccgaattcactggggagagcattcagg ; 5'cgggatcccggggagaagtttggttgtatgtttcg. The fragment was purified and subcloned (BamH1/Kpn1) into pEGFP-1 vector (Clontech) in front and in frame of the EGFP coding sequence.
Transient transfections
Jurkat E6-1 or Jurkat Tag cells were transiently transfected using DMRIE-C reagent, according to the Manufactures protocol (Life Technologies). Cells were transfected with 1 to 4 ug DNA/2x10 6 cells using 4 ul DMRIE-C reagent. The transfection was made in pure RPMI 1640 (without supplements) and cells were incubated 4-5h at 37°C (final volume 1.2 ml), prior to addition of 2 ml conditioned RPMI 1640 media (containing 10% FBS) and further culturing over night.
In vivo experiments with NOD mice
Female NOD mice were screened for development of diabetes by twice weekly measurement of urinary sugar. When urinary sugar was positive the blood sugar was measured twice weekly. The mice were injected twice a week i.p. with 8 µg FR901228 or vehicle control for maximum 8 weeks following initiation of diabetes. Treatment was initiated at the beginning of diabetes development when the blood-glucose level rose above 10 mM. Mice with a blood-glucose level exceeding 15 mM at the time of treatment initiation were not included in the study. Mice were monitored for at least 3 weeks For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From
Results
HDAC-i inhibit activation-induced proliferation of normal T cells
We have investigated the effect of HDAC-i on activation-induced T cell proliferation.
Peripheral blood lymphocytes (PBL) were treated with various concentrations of the HDAC-i FR901228 1h prior to stimulation with antibodies against CD3 and CD28 coupled to paramagnetic beads (3x28 beads), ionomycin/PMA or in vitro derived allogeneic dendritic cells. Concentrations of FR901228 down to 5-10 ng/ml inhibited proliferation of PBL cultures (Fig 1a-c) . Proliferation induced by allogeneic dendritic cells was significantly inhibited by FR901228 at concentrations down to 1 ng/ml (Fig 1c) .
Presence of 1 ng/ml FR901228 or below had no significant effect on 3x28 beads or ionomycin/PMA induced proliferation (Fig 1a and b) . To verify these results we used CFSE labeled PBL cultures stimulated with 3x28 beads for 6 days (Fig 1d) , in this assay proliferation is measured by flow cytometry as decrease in CFSE fluorescence intensity due to segregation of CFSE between daughter cells. Addition of 20 ng/ml FR901228 at the time of stimulation (Fig 1d) or up to 6h after stimulation (not shown) completely inhibited proliferation. Furthermore, FR901228 added to the culture 24h after 3x28 bead stimulation stopped proliferation at this time point, demonstrating that FR901228 can inhibit ongoing proliferation (Fig 1d) . Simultaneous staining for CD4 and CD8 showed that FR901228 inhibited CD4 and CD8 T cells to a similar extent (not shown).
FR901228 inhibited proliferation of highly purified CD4 cells at concentrations comparable to those that inhibit PBL cultures (Fig 1e) , implying that HDAC-i directly targets T cells. Trichostatin A, a structurally unrelated HDAC-i, also inhibited stimulation induced proliferation of PBL (Fig 1f) and purified CD4 cultures (not shown), strongly suggesting that inhibition of HDAC activity, and not a secondary effect, is responsible for the proliferation arrest.
Figure 1:
HDAC-i inhibit T cells prior to S-phase entry and does not induce apoptosis in stimulated naive T cells
To investigate the cause of proliferation inhibition, FR901228 treated cells were analyzed for viability, cell cycle progression and apoptosis. Viability was measured by cell membrane integrity. 7-AAD staining of DNA was used to follow progression from G1 -S -G2 phase of the cell cycle, Annexin-V and sub-G1 DNA staining was used to monitor apoptosis.
Addition of FR901228 at doses up to 100 ng/ml had very low effect on PBL viability within 24h (Fig 2a) , emphasizing that the inhibitory effect of HDAC-i is not caused by a cytotoxic effect. These results correlate with a previous report in which 24h exposure of PBMC cultures to FR901228 was shown to have an LC50 value on ~965 nM 2 . In the previous study PBMC cells was exposed to FR901228 for 24h, but viability was measured after 4 days, the LC50 value immediately after 24h exposure is thus almost certainly higher.
Intracellular DNA staining after 24h of stimulation showed that FR901228 arrested 3x28 bead stimulated T cells in the G1-phase, prior to S-phase entry (Fig 2b) . Concentrations of FR901228 at 1 ng/ml or below had no effect on cell cycle progression and cells can be seen to enter the S phase similarly to stimulated cells that were not exposed to FR901228 (Fig 2b) . These data correlate with the level of FR901228 that caused inhibition of proliferation. The intracellular DNA staining did not detect signs of apoptosis by highly condensed DNA, which can be seen as a sub G1 peak (Fig 2b) . This observation was supported by negative annexin V staining of naive PBLs exposed to FR901228 for 24h
(not shown).
In conclusion, FR901228 arrest recently activated naive PBLs in the G1 phase without affecting viability. 
HDAC-i does not inhibit the very proximal signaling after CD3/CD28 stimulation
We wished to examine the mechanism behind HDAC-i inhibition of activation-induced proliferation. The proximal intracellular signal pathways in naive CD4 cells were not inhibited by HDAC-i. Thus the immediate tyrosine phosphorylation after anti-CD3
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Furthermore, the rise in intracellular calcium concentration after anti-CD3 stimulation of PBL was not affected by FR901228 (Fig 3) . These data suggests that the very proximal signals after TCR/CD3 engagement were not altered by HDAC-i. 
HDAC-i inhibits activation-induced CD154 and CD25 expression on CD4 cells
To further characterize HDAC-i inhibition of T cells, we measured changes in surface expression of activation molecules. As expected, there was a robust induction of the IL-2 receptor α-chain (CD25), the CD40 ligand (CD154) and the CD69 molecule on the surface of peripheral CD4 T cells 24h after 3x28 bead stimulation (Fig 4a-c) . Inclusion of FR901228 down to 10 ng/ml completely suppressed the induction of CD25 and CD154
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Activation-induced T cell aggregation is abrogated by HDAC-i
Activated T cells rapidly adhere into characteristic aggregates; these aggregates can be formed as homotypic aggregates between T cells themselves or heterotypic aggregates between T cells and antigen presenting cells (heterotypic aggregation). The specific adhesion is caused by increased surface expression and/or activation of adhesion molecules, primarily LFA-1, ICAM-1, ICAM-3 and CD2 on the T cell and ICAM-1, ICAM-2 and LFA-3 on the APC. Aggregation of PBLs 24h after 3x28 bead stimulation was completely abolished by FR901228 or Trichostatin A (Fig 5a) . Aggregation of highly purified 3x28 bead activated CD4 cells was also inhibited by HDAC-i (not shown). A likely explanation for the deficient aggregation is that expression of adhesion molecules is compromised by HDAC-i. To investigate this in greater detail, expression of CD11a (the LFA-1 specific α-chain) and CD54 (ICAM-1) was monitored. FR901228 and Trichostatin A completely inhibited activation-induced expression of CD11a and CD54 expression on CD4 T cells (Fig 5b) . There was a significant expression of CD11a and a weak expression of CD54 on non-activated CD4 T cells, basal expression of both molecules was reduced by HDAC-i treatment although not to undetectable levels (fig 5b) . part, due to diminished expression of LFA-1 and ICAM-1 molecules.
We have previously shown that the molecular pathway leading to IL-2 induced T cell aggregation is not directly linked to proliferation 24 . Thus, although lack of aggregation following T cell activation is a significant sign of inhibition, it is not necessarily involved in growth inhibition. For
HDAC-i inhibits IL-2 production by activated peripheral T cells
A hallmark of CD4 T cell activation is production of IL-2. In order to make efficient amounts of IL-2 T cells needs co-stimulation, normally from the CD28 molecule.
FR901228 or Trichostatin A markedly inhibited IL-2 production, as measured by ELISA 24 h after 3x28 bead stimulation of PBL cultures (Fig 6a) ; a result that was confirmed by intracellular IL-2 staining of CD4 T cells (Fig 6b) . In agreement with the earlier observed inhibitory capacity of FR901228, 100 nM and 10 nM completely inhibited IL-2 production whereas 1 nM had no effect (Fig 6b) (brefeldin A/monensin was omitted in these experiments, which causes a smaller increase in intracellular IL-2 staining, in our hands this however more appropriately reflects the actual level of IL-2).
The diminished IL-2 production was not by itself responsible for the lack of proliferation, as addition of 1000 IU/ml IL-2 could not restore proliferation (not shown). A finding that is not surprising given the fact that HDAC-i treatment also inhibits CD25 expression. 
Molecular mechanism behind HDAC-i inhibition of CD154 expression
To understand the molecular mechanism behind HDAC-i inhibition of T cell activation, regulation of CD154 was investigated more thoroughly. 
Recently, Stortz et al. showed that T cells from patients with the rare skin cancer Mycosis
Fungoides have constitutive surface-expression of CD154 33 . We could confirm their results in various MF cells lines generated in our laboratory; again CD154 expression was not affected by Cyclosporine, but was completely inhibited by FR901228 (Fig 7b) . A fraction of Jurkat T cells have constitutive expression of CD154 when measured by intracellular staining (CD154 is weakly expressed on the surface of Jurkat cells). CD154
expression was again completely inhibited by FR901228 and not affected by Cyclosporine (Fig 7b) . These data suggest that HDAC-i inhibits CD154 expression on activated T cells and cancer T cells lines by a mechanism distinct from calcineurin/NF-AT inhibition.
To investigate if HDAC-i directly inhibits transcriptional activation of the CD154 gene,
Jurkat cells were transiently transfected with a vector containing 2kb of the proximal CD154 promoter in front of a GFP coding sequence. As expected, there was constitutive, although relatively weak, CD154 promotor activity in Jurkat cells, which was enhanced by stimulation with anti-CD3 stimulation (Fig 7c) . FR901228 or Trichostatin A completely inhibited basal and TCR induced CD154 promoter activity (Fig 7d) , as promotor activity (Fig 8c) . These results strongly suggest that c-Myc expresssion is essential for CD154 expression in Jurkat cells, both the NF-AT dependent and independent pathways. It should be noted that the modulation of CD154 promotor activity varied with the ratio and end-concentration of the transfected plasmids. 
HDAC-i inhibits diabetes development in NOD mice
To investigate the T cell inhibitory capacity of HDAC-i in vivo, we made use of NOD mice that spontaneously develop diabetes due to T cell mediated destruction of the insulin producing β-cells in the pancreas. Mice were treated with vehicle or ~0.5 mg/kg FR901228 i.p. 2 times a week for a period of 8 weeks. To evaluate if FR901228 could inhibit an ongoing auto-aggressive immune attack, treatment was first initiated when the mice developed signs of diabetes (blood glucose levels above 10 mM and glucosuria).
In the control group receiving vehicle, 6 out of 7 mice developed overt diabetes (defined as blood sugar exceeding 20 mM in two consecutive measurements), which was in contrast to the group treated with FR901228 where 1 out of 4 mice developed diabetes (Fig 9) . These results suggest that FR901228 can inhibit ongoing immune responses in vivo.
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Discussion
In this report we describe that inhibition of histone deacetylases results in a profound inhibition of both CD4 and CD8 T cell activation. We observed similar inhibition using 2 structurally unrelated HDAC-i, FR901228 and Trichostatin A, suggesting that inhibition of deacetylase activity, and not a secondary effect, is the mechanism of action. In favor of this argument, we found that Previous studies have shown that HDAC-i inhibit tumor cell growth both in the G1 and G2 cell cycle phase 11;14;18 . We did not observe a G2 arrest, most likely because the naive T cells stimulated in the presence of HDAC-i were arrested in the G1 phase before they had a chance to enter the G2 phase. It has been noted that mainly the G2 arrest is associated with apoptosis/cytotoxicity 13 , which could very well account for the specific induction of apoptosis in tumor cells compared to normal-noncycling cells. In line with this, Byrd et al. showed very limited cytotoxicity on PBMC cultures using 2 . A recent phase I clinical trial of FR901228 showed a maximal tolerated dose of 24.9 mg/m 2 , which gave a mean maximum plasma concentration of 472.6 ng/ml 35 .
It thus seems reasonably to conclude that the inhibition of T cell proliferation we observe (full inhibition at 10 -20 ng/ml FR901228) is not caused by aberrant cytotoxic effects.
We found that HDAC-i inhibited IL-2 production from activated CD4 T cells, this does not correlate with a previous study from Wang et al. who showed that FR901228 could not inhibit CD3 induced IL-2 production from the A1.1 T cell hybridoma line 15 . The reason for the apparent difference is not obvious, but different signal pathways could of course be responsible for IL-2 production in each circumstance. Our data concerning inhibition of IL-2 production from PBL cultures by FR901228 or Trichostatin A was reproduced with cells from 4 different donors, no exceptions were observed. We thus conclude that HDAC-i inhibits IL-2 production by recently activated CD4 T cells from peripheral blood.
Although inhibition of T cell proliferation is vital for immunosuppression, it is equally important to inhibit the stimulatory "effector" molecules expressed on activated T cells.
We have focused our attention on the CD154 molecule because of its wide-ranging importance in activation of the main parts of the acquired immune system, including activation of CD8 T cells, B cells, dendritic cells and macrophages 25 .
The importance of CD154 expression is convincingly illustrated in knock-out mice missing either CD154 or CD40 and in humans with a genetic defect in the CD154 gene, which all have a severely impaired immune system 25 . CD154 is mainly expressed on recently activated CD4 T cells by an NF-AT dependent mechanism involving the Cyclosporine/FK-506-sensitive phosphatase calcineurin [29] [30] [31] . We have earlier demonstrated that IL-2 and IL-15 can induce CD154 expression on activated effector CD4 T cells by a signal pathway that is independent from calcineurin activation 32 .
Constitutive or elevated CD154 expression is often seen in situ during autoimmune attacks and blockade of CD154/CD40 interaction has proven to be highly beneficial for treatment of autoimmune disorders [36] [37] [38] [39] [40] [41] , making pharmacological inhibitors of CD154
highly relevant for treatment of autoimmune disorders.
While Cyclosporine and FK-506 effectively prevents graft rejection and is currently standard therapy, their effectiveness towards prevention of an ongoing autoimmune attack is minimal. It is tempting to speculate that the relatively weak therapeutic effect of Cyclosporine towards autoimmune diseases, to a significant part, stems from the lack of effective down modulation of CD154 expression on activated T cells.
In this report we show that the FR901228 or interaction during the primary T cell activation can lead to specific tolerance towards the stimulatory antigen. This specific tolerance could be adoptively transferred by an antigen presenting cell with similarities to both dendritic cells and NK cells 42 .
In conclusion our studies suggests that HDAC-i may be a potential candidate for clinical treatment of autoimmune disorders and allograft rejection. However when used as antitumor therapy, the primarily unwanted immunosuppressive activity of HDAC-i should be taken into account -although the transient and non-cytotoxic nature of the suppression may be tolerable in this circumstance. For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From
